Insiders 89bio, Inc.

Equities

ETNB

US2825591033

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
8.07 ^USD	-2.83%		+0.62%	-27.75%

May. 22	89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis at EASL International Liver Congress	CI
May. 14	89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis Patients with Compensated Cirrhosis	CI

Insiders

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

89bio, Inc. Appoints Martin Babler to Its Board of Directors	Apr. 17	CI
89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	Apr. 03	MT
89bio Insider Sold Shares Worth $560,000, According to a Recent SEC Filing	Jan. 03	MT
89Bio, Inc. Announces Board Changes	23-08-15	CI
Insider Sell: 89bio	23-06-07	MT
Insider Sell: 89bio	23-06-05	MT
Insider Sell: 89bio	23-05-11	MT
Insider Sell: 89bio	23-04-06	MT
Insider Buy: 89bio	23-03-30	MT
Insider Sell: 89bio	23-03-03	MT
Spruce Biosciences Names New Chief Medical Officer	22-03-14	MT
89bio, Inc. Appoints Edward Morrow Atkinson to the Board	22-02-24	CI
89bio Announces Appointment of Kathy Laporte to Its Board of Directors	21-11-03	CI
Insider Sell: 89bio	21-10-20	MT
Insider Sell: 89bio	21-09-20	MT
Anat Naschitz to Resign as Member of the Board of 89bio, Inc	21-07-30	CI
89bio Appoints Lota Zoth to Board of Directors	20-06-04	CI
89bio, Inc. Appoints Steven Altschuler, M.D., as Chairman of the Board of Directors	20-03-25	CI
89Bio, Inc. Announces Resignation of Tomer Kariv from the Board of Directors	19-12-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer